Susquehanna International Group, LLP Viking Therapeutics, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$49.84 - $70.47 $29.7 Million - $42 Million	-595,500 Reduced 31.08%	1,320,400 $83.6 Million
Q2 2024 Aug 15, 2024	SELL	$47.39 - $80.2 $41.8 Million - $70.7 Million	-882,100 Reduced 31.53%	1,915,900 $102 Million
Q1 2024 May 07, 2024	BUY	$17.4 - $94.5 $39.2 Million - $213 Million	2,253,100 Added 413.49%	2,798,000 $229 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $1.23 Million - $2.62 Million	133,500 Added 32.45%	544,900 $10.1 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $1.82 Million - $2.66 Million	-166,500 Reduced 28.81%	411,400 $4.55 Million
Q2 2023 Aug 11, 2023	BUY	$14.84 - $24.79 $3.42 Million - $5.71 Million	230,300 Added 66.25%	577,900 $9.37 Million
Q1 2023 May 16, 2023	BUY	$8.08 - $17.33 $2.12 Million - $4.55 Million	262,700 Added 309.42%	347,600 $5.79 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $56,304 - $194,580	20,700 Added 32.24%	84,900 $798,000
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $102,000 - $155,600	40,000 Added 165.29%	64,200 $175,000

473

65.6M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.27B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.